iSpecimen (ISPC) Common Equity (2020 - 2026)

iSpecimen (ISPC) has reported Common Equity for 7 consecutive years, with $814038.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Common Equity fell 51.21% year-over-year to $814038.0; the TTM figure through Mar 2026 stood at $814038.0 (down 51.21% YoY), while the FY2025 annual figure was $3.1 million, down 6.73% from the prior year.
• Common Equity came in at $814038.0 for Q1 2026 at iSpecimen, down from $3.1 million in the prior quarter.
• The five-year high for Common Equity was $27.7 million in Q1 2022, with the low at $621973.0 in Q2 2025.
• Average Common Equity over 5 years is $10.7 million, with a median of $6.8 million recorded in 2024.
• Across the five-year window, Common Equity soared 188.62% in 2022 and plunged 89.79% in 2025, its largest moves.
• Year by year, Common Equity stood at $20.3 million in 2022, then tumbled by 52.04% to $9.7 million in 2023, then tumbled by 66.01% to $3.3 million in 2024, then fell by 6.73% to $3.1 million in 2025, then plunged by 73.64% to $814038.0 in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $814038.0, $3.1 million, and $3.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.